NAD+ Doesn't Decline With Age? What the Headlines Aren't Telling You
NAD+ Doesn't Decline With Age? What the Headlines Aren't Telling You
Over the past few weeks, several media outlets have reported that NAD+ may not necessarily decline with age.
For some readers, this seems to challenge the very foundation of longevity strategies focused on NAD+ restoration.
But that conclusion is misleading.
More importantly, it does not accurately reflect what the scientific evidence actually shows.
When Scientific Nuance Becomes a Sensational Headline
Recent publications do not claim that NAD+ is unimportant.
What they suggest is that NAD+ decline is not identical across all individuals, tissues, and physiological conditions.
This is an important nuance.
However, it does not change three fundamental facts:
✔ NAD+ remains one of the most essential molecules in cellular metabolism.
✔ It plays a central role in mitochondrial energy production, sirtuin activity, and DNA repair.
✔ Human clinical studies continue to demonstrate that NAD+ levels can be significantly increased through appropriate supplementation.
The current debate is therefore about the variability of NAD+ decline.
Not about its biological importance.
The Question Most Headlines Never Ask
Even when certain tissues maintain relatively stable NAD+ levels, aging is often accompanied by:
-
Increased oxidative stress
-
Chronic low-grade inflammation
-
Elevated CD38 activity, a major NAD+-consuming enzyme
-
Greater demand for DNA repair mechanisms
-
Progressive mitochondrial dysfunction
In other words, cellular demands evolve with age.
The question is not simply whether NAD+ levels decline.
The question is whether the body retains sufficient metabolic resources to meet these increasing biological demands.
This distinction is critical.
A stable reservoir does not necessarily mean optimal availability when demand continues to rise.
What the Clinical Evidence Actually Shows
Over the last decade, human studies investigating NAD+ precursors such as NMN and nicotinamide riboside (NR) have consistently shown that supplementation can increase circulating NAD+ levels.
These studies have also demonstrated favorable safety and tolerability profiles when high-quality ingredients are manufactured under rigorous standards.
Recent headlines have not changed this reality.
What they have done is highlight the need for more precise human data.
This is precisely why Seneque chose a different path.
Why Seneque Took a Different Approach
Today, hundreds of brands sell NMN products.
Very few invest in generating their own clinical evidence.
Rather than relying exclusively on existing academic literature, Seneque developed and clinically evaluated its proprietary ingredient: NMN-C®.
Our objective was simple.
Generate human data.
Measure biological outcomes.
Understand how NMN-C® behaves in the human body.
And contribute meaningful evidence to the scientific understanding of NAD+ metabolism.
Clinical Trial #1: Tolerability and Impact on NAD+ Levels
To evaluate the safety and biological activity of NMN-C®, Seneque conducted a clinical study in healthy adults examining the effects of daily supplementation over a 28-day period.
The study investigated:
-
Safety
-
Tolerability
-
Changes in circulating NAD+ levels
-
NAD+-related metabolites
The full clinical protocol is publicly available through ClinicalTrials.gov:
What Makes This Study Different?
Rather than measuring only a single endpoint, researchers evaluated multiple biomarkers involved in NAD+ metabolism.
Blood samples were collected at numerous time points throughout the study to characterize both acute and long-term responses.
Among the biomarkers monitored were:
-
NAD+
-
NMN
-
Nicotinamide (NAM)
-
Methyl-nicotinamide (MeNAM)
-
Other downstream metabolites involved in NAD+ turnover
These measurements provide a much deeper understanding of how supplementation influences the entire NAD+ metabolic network.
Key Findings
The study demonstrated that NMN-C® was well tolerated under the conditions investigated.
No significant safety concerns were identified during the intervention period.
Importantly, supplementation resulted in measurable increases in circulating NAD+ levels, confirming that NMN-C® effectively engages human NAD+ metabolism.
The data also revealed active turnover of NAD+-related metabolites, suggesting that supplementation was not merely increasing a laboratory marker but interacting with the broader NAD+ recycling system.
Clinical Trial #2: Pharmacokinetics and Biological Utilization of NMN-C®
The second clinical study was designed to answer a different question:
What happens to NMN-C® after ingestion?
The study explored:
-
Absorption
-
Distribution
-
Metabolism
-
Elimination
-
NAD+-related biomarker responses
The complete protocol can be accessed here:
Why Pharmacokinetics Matter
Increasing NAD+ levels is only part of the story.
To understand the true biological relevance of a compound, researchers must determine how it is absorbed, transformed, and utilized by the body.
The study showed that NMN-C® is efficiently absorbed and integrated into human NAD+ biosynthetic pathways.
Researchers observed characteristic changes in metabolites associated with NAD+ synthesis, recycling, and elimination.
These findings provide valuable insight into how NMN-C® participates in cellular NAD+ metabolism after oral administration.
Understanding NAD+ Turnover
One of the most important concepts emerging from modern NAD+ research is turnover.
NAD+ is not a static molecule.
Cells continuously produce it, consume it, recycle it, and regenerate it.
Processes such as DNA repair, mitochondrial function, immune signaling, and cellular stress responses all require NAD+.
As we age, many of these pathways become increasingly active.
Consequently, maintaining adequate NAD+ availability may become just as important as maintaining absolute NAD+ levels.
The pharmacokinetic data generated with NMN-C® contribute to a growing understanding of how NAD+ precursors support this dynamic biological system.
Beyond NAD+ Levels: The Bigger Picture
The latest scientific discussions surrounding NAD+ are valuable because they encourage researchers to ask better questions.
But they should not be interpreted as evidence against NAD+ biology.
In fact, the opposite is true.
The more we learn, the clearer it becomes that NAD+ metabolism is highly complex, tightly regulated, and deeply connected to many hallmarks of aging.
The real challenge is no longer proving that NAD+ matters.
The challenge is understanding how best to support NAD+ metabolism in humans throughout the aging process.
When Others Discuss NAD+, Seneque Generates Data
The longevity industry is increasingly crowded with marketing claims.
Clinical evidence remains comparatively rare.
At Seneque, we chose a different path.
Develop a proprietary ingredient.
Evaluate it in humans.
Measure its biological impact.
Generate clinical evidence.
And continue contributing to the scientific understanding of healthy aging.
This commitment is reflected in the development of NMN-C®, the proprietary ingredient used in ELEVANT®, our premium NAD+ support program.
What We Take Away From This Debate
Scientific debates are healthy.
They refine our understanding and help separate assumptions from evidence.
But they do not change one essential fact:
NAD+ remains one of the most extensively studied molecules in the field of longevity science.
And human clinical research continues to demonstrate that NAD+ metabolism can be effectively supported through well-designed precursor supplementation strategies.
At Seneque, we do not follow headlines.
We follow data.
Because in longevity science, evidence will always outlast trends.
Discover ELEVANT® and explore the research behind NMN-C®, Seneque's proprietary approach to supporting healthy NAD+ metabolism and the next generation of longevity science.